Last Updated: November 15, 2026

Details for Patent: 10,583,121

« Back to Dashboard


Summary for Patent: 10,583,121
Title:Patch
Abstract:A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC2-120 for a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pg·hr/mL or more, and an AUC2-120 of an asenapine metabolite is 20% or less of the AUC2-120 of the free asenapine.
Inventor(s):Masayuki Suzuki, Hiroaki Okutsu, Takashi Yasukochi, Yasunori Takada
Assignee: Hisamitsu Pharmaceutical Co Inc
Application Number:US15/454,066
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

US Patent 10,583,121: Asenapine Transdermal Patch Claims, Expiration, Orange Book Status, and Generic Risk

US Patent 10,583,121 protects a specific asenapine transdermal patch architecture and a defined pharmacokinetic performance profile. The core combination is a styrene-isoprene-styrene adhesive, sodium diacetate, isopropyl palmitate, and asenapine, preferably asenapine maleate. The independent claims also require a normalized 24-hour exposure threshold and suppression of an asenapine metabolite.

The patent is materially narrower than a generic claim to any asenapine patch. A competing product would need to avoid at least one required structural component, numerical formulation range, or pharmacokinetic limitation to reduce literal infringement risk. Because the claims include measurable composition and exposure limitations, invalidity and non-infringement disputes would likely focus on enablement, written description, claim construction, formulation testing, and pharmacokinetic reproducibility.

What does US Patent 10,583,121 protect?

US Patent 10,583,121 protects an asenapine patch having both a defined formulation and a defined systemic exposure profile.

Required element Scope of requirement
Dosage form Patch for transdermal administration
Physical structure Support layer plus adhesive agent layer
Adhesive base 10% to 90% by mass of the adhesive layer
Required polymer Styrene-isoprene-styrene block copolymer
Required additive Sodium diacetate
Required permeation enhancer Isopropyl palmitate
Active ingredient Asenapine or pharmaceutically acceptable salt
Dose normalization 3.4 mg of free asenapine
Exposure requirement AUC2-120 of free asenapine of at least 27,000 pg·hr/mL
Metabolite requirement Metabolite AUC2-120 no more than 20% of free-asenapine AUC2-120

The patent does not cover every asenapine transdermal delivery system. Its central limitation is the combination of adhesive chemistry and pharmacokinetic performance.

The claims cover products that satisfy the listed components even if the product has additional ingredients, provided the additional ingredients do not remove or alter a required element. A patch with a different adhesive polymer, no sodium diacetate, or no isopropyl palmitate would present a stronger literal non-infringement position.

How broad is independent claim 1?

Claim 1 is a composition-and-performance claim. It requires:

  1. A support layer.
  2. An adhesive layer on the support.
  3. An adhesive base agent containing styrene-isoprene-styrene block copolymer.
  4. Adhesive base agent content of 10% to 90% by mass.
  5. Sodium diacetate.
  6. Isopropyl palmitate.
  7. Asenapine or a pharmaceutically acceptable salt.
  8. A normalized asenapine dose of 3.4 mg for the pharmacokinetic limitation.
  9. Free-asenapine AUC2-120 of at least 27,000 pg·hr/mL.
  10. Metabolite AUC2-120 of no more than 20% of the free-asenapine AUC2-120.

The claim is structurally narrower than a conventional Markush claim covering any adhesive, enhancer, or salt. It is functionally broader in one respect because it does not require a specific commercial patch size, total drug loading, release rate, backing material, or named metabolite in the text supplied.

What formulation components are protected?

The required formulation components are cumulative:

  • Styrene-isoprene-styrene block copolymer
  • Sodium diacetate
  • Isopropyl palmitate
  • Asenapine or its pharmaceutically acceptable salt

The claim does not require a tackifier or softener. Those ingredients appear only in dependent claims 6 through 9 and the corresponding method claims.

The 10% to 90% adhesive-base range is broad. It leaves substantial formulation latitude for the proportions of drug, sodium diacetate, isopropyl palmitate, tackifier, softener, and other excipients. The formulation still must produce the claimed pharmacokinetic result.

What do claims 2 through 10 add?

Claims 2 through 10 narrow the patch claim through composition and ratio limitations.

Claim Added limitation
2 Asenapine-to-sodium-diacetate mole ratio of 1:0.5 to 1:4
3 Pharmaceutically acceptable salt is asenapine maleate
4 Asenapine content, calculated as free asenapine, is 1% to 15% by mass
5 Free-asenapine-to-isopropyl-palmitate mass ratio is 1:0.1 to 1:10
6 Adhesive layer includes a tackifier
7 Adhesive-base-to-tackifier mass ratio is 1:6 to 1.5:1
8 Adhesive layer includes a softener
9 Adhesive-base-to-softener mass ratio is 1:6 to 5:1
10 Combines the claim 2 mole ratio and claim 4 drug-content range

The most commercially relevant dependent claims are claims 3, 4, 5, and 10. Asenapine maleate is the principal pharmaceutical form used in the marketed product lineage. Claims 4 and 10 impose formulation windows that could capture practical commercial formulations while narrowing the claim against design-around products.

What do claims 11 through 20 protect?

Claims 11 through 20 are method-of-treatment claims. They recite treatment of a central nervous system disease by applying the claimed patch to a patient's skin.

The method claims largely repeat the product limitations. They do not create a broad method claim covering oral or sublingual asenapine. They require use of a patch having the same adhesive composition and pharmacokinetic profile as claim 1.

Potentially relevant diseases include conditions for which asenapine is used as an antipsychotic, particularly schizophrenia and bipolar I disorder. The supplied claim language uses the broader expression "central nervous system disease." That wording may create scope and enablement issues if the specification does not support treatment across the full breadth of central nervous system disorders.

What is the significance of the method-of-use claims?

The method claims can create infringement exposure for:

  • A manufacturer that induces use of an infringing patch.
  • A distributor that markets the patch for the claimed treatment.
  • A healthcare provider or patient using the product, although enforcement is ordinarily directed at commercial actors.
  • An ANDA applicant whose labeling instructs use for the claimed disease.

The method claims may remain relevant after a formulation claim is challenged, but their enforceability depends on the same composition and pharmacokinetic limitations. A noninfringing patch formulation would generally avoid both the product claims and the corresponding method claims.

When does US Patent 10,583,121 expire?

The patent has a 20-year term measured from the relevant nonprovisional or international filing date, subject to any patent-term adjustment. The published patent record identifies a 2016 priority framework for the asenapine patch technology. The expected nominal expiration is in 2036, with the exact effective expiration dependent on the patent's term-adjustment calculation and any terminal disclaimer.

Event Date or period
Priority development 2015-era Japanese priority filings
International/PCT filing framework 2016
US patent grant March 10, 2020
Nominal patent term Approximately 2036
Patent-term adjustment Must be confirmed from the USPTO patent-term calculation
FDA product approval for Secuado October 11, 2019

Patent expiration should not be treated as identical to FDA exclusivity expiration. FDA marketing exclusivity for a new dosage form can expire years before the listed patent.

What is the FDA and Orange Book status of the asenapine patch?

The FDA approved Secuado, an asenapine transdermal system, on October 11, 2019, for the treatment of adults with schizophrenia. Secuado is a transdermal formulation of asenapine and was developed by Noven Pharmaceuticals, a company within the Hisamitsu group.

Regulatory item Status
Product Secuado
Active ingredient Asenapine
Dosage form Transdermal system
Applicant Noven Pharmaceuticals, Inc.
FDA approval October 11, 2019
Initial indication Schizophrenia in adults
Regulatory pathway NDA
New chemical entity exclusivity No, asenapine was previously approved as Saphris
New clinical investigation exclusivity Generally three years for the new dosage form, subject to FDA Orange Book coding
Orange Book patent relevance Product-specific patent listings control ANDA certification obligations

The FDA initially approved asenapine sublingual tablets under the brand Saphris in 2009. Secuado therefore did not receive five-year new chemical entity exclusivity. Its principal regulatory protection came from the new dosage form, clinical data, and patent estate.

An ANDA applicant challenging a listed patent may submit a Paragraph IV certification. If the NDA holder brings suit within 45 days, FDA approval can be stayed for up to 30 months, subject to statutory exceptions and later court developments.

How strong is the patent estate for Secuado?

The estate is strongest against a transdermal product that replicates the commercial formulation architecture. It is weaker against a materially different patch platform.

Strengths

  • The claims require several specific formulation ingredients.
  • The pharmacokinetic limitation links the formulation to a measurable therapeutic exposure.
  • Claims cover both the patch and treatment using the patch.
  • Dependent claims provide narrower fallback positions for asenapine maleate and quantitative formulation ranges.
  • The patent term extends well beyond the product's three-year regulatory exclusivity period.

Vulnerabilities

  • The AUC limitation may require detailed testing and raise questions about assay methodology and subject variability.
  • The claim refers to an "asenapine metabolite" without the supplied language identifying a single metabolite. Claim construction may be disputed.
  • The phrase "when ... the content ... is 3.4 mg" creates a normalization issue for products with different drug loading.
  • A competitor may use a different pressure-sensitive adhesive system.
  • A competitor may replace sodium diacetate or isopropyl palmitate while preserving transdermal delivery.
  • The broad "central nervous system disease" language may face written-description or enablement scrutiny depending on the specification.

The patent is therefore more effective as a formulation-specific barrier than as a platform patent covering all asenapine patches.

What generic entry risks exist?

A conventional generic tablet does not directly practice the transdermal patch claims. A generic or follow-on product would need to be a transdermal asenapine system to face the principal claim set.

Likely entry scenarios

Entry scenario Patent risk
Generic sublingual asenapine tablet Limited exposure to this patent
Transdermal patch using the same four required ingredients High literal infringement risk
Patch using asenapine maleate and claimed ratios Higher risk
Patch using a different adhesive polymer Reduced literal infringement risk
Patch without sodium diacetate Reduced literal infringement risk
Patch without isopropyl palmitate Reduced literal infringement risk
Patch with materially different exposure profile Possible non-infringement, subject to testing
Non-ANDA branded transdermal product Patent and regulatory litigation risk remains

A Paragraph IV challenge would likely attack the patent on obviousness, lack of written description, enablement, indefiniteness, or failure to satisfy the claimed pharmacokinetic relationship. The challenger could also argue that the claimed excipient combination and transdermal delivery objective were predictable from prior art involving asenapine, pressure-sensitive adhesives, permeation enhancers, and acidifying agents.

Which companies are positioned in the asenapine market?

Company Product or role Relevance
Noven Pharmaceuticals Secuado developer and NDA applicant Commercial transdermal product
Hisamitsu Pharmaceutical Parent/group company associated with Noven Patent and commercial ownership context
Organon and prior Schering-Plough entities Saphris commercialization history Sublingual asenapine market
Generic manufacturers Potential ANDA applicants Primarily relevant to oral asenapine unless developing patches

The principal competitive distinction is between oral or sublingual asenapine and transdermal asenapine. An oral generic does not substitute for Secuado in every regulatory or clinical context because dosage form, administration, adherence, and pharmacokinetic profiles differ.

Does biosimilar risk apply to asenapine?

No. Asenapine is a small-molecule active pharmaceutical ingredient, not a biologic. Biosimilar approval under the Public Health Service Act is not the applicable pathway.

Competitive entry would proceed through an ANDA for a pharmaceutically equivalent product or through a separate NDA for a materially different transdermal product. The primary legal mechanisms are Paragraph IV certification, patent litigation, Hatch-Waxman stays, and possible settlement agreements.

What litigation and settlement issues affect the patent?

The key litigation trigger would be an ANDA or competing NDA for an asenapine transdermal system that references Secuado or relies on its formulation and clinical data.

The relevant dispute points would include:

  1. Whether the accused adhesive contains a styrene-isoprene-styrene block copolymer.
  2. Whether the adhesive-base content falls within 10% to 90%.
  3. Whether sodium diacetate and isopropyl palmitate are present.
  4. Whether the drug content falls within the claimed ranges.
  5. Whether the accused product satisfies the AUC2-120 limits.
  6. Whether the metabolite limitation is definite and reproducible.
  7. Whether the asserted claims are obvious in view of prior transdermal asenapine formulations.
  8. Whether the method claims are induced by the proposed labeling.

No settlement terms should be inferred merely from a Paragraph IV filing. Hatch-Waxman cases can end through license agreements, delayed-entry settlements, consent judgments, or claim narrowing. A settlement could grant an authorized generic license or establish a date earlier than patent expiration, but the supplied record does not establish such an agreement.

How does US Patent 10,583,121 compare with the oral asenapine estate?

Issue Transdermal asenapine Oral or sublingual asenapine
Representative product Secuado Saphris
Administration Skin patch Sublingual tablet
Main patent focus Adhesive composition and exposure profile Active ingredient, formulation, method of treatment
Key regulatory product 2019 NDA 2009 NDA
Biosimilar pathway Not applicable Not applicable
Generic substitution Requires transdermal equivalent Oral generic pathway
Main commercial barrier Patch formulation and patent estate Earlier oral product patents and regulatory exclusivity

The patent at issue is not a basic asenapine composition-of-matter patent. Its commercial value depends on the transdermal delivery system, product differentiation, and the ability to enforce formulation and pharmacokinetic limitations.

Key Takeaways

  • US Patent 10,583,121 covers a specific asenapine patch, not every asenapine transdermal product.
  • The required formulation includes styrene-isoprene-styrene, sodium diacetate, isopropyl palmitate, and asenapine or its salt.
  • The claims require free-asenapine AUC2-120 of at least 27,000 pg·hr/mL and metabolite exposure of no more than 20% of the asenapine exposure.
  • Claims 11 through 20 extend the same limitations to treatment methods for central nervous system disease.
  • The patent has an expected term into approximately 2036, subject to USPTO patent-term adjustment.
  • Secuado received FDA approval in 2019 as a transdermal asenapine product for schizophrenia.
  • Three-year new clinical investigation exclusivity is separate from the patent term and does not create five-year NCE protection.
  • Generic oral asenapine does not directly practice the transdermal claims.
  • A competing transdermal patch would face the highest risk if it uses the same adhesive polymer, sodium diacetate, isopropyl palmitate, and exposure profile.
  • The strongest design-around options involve a different adhesive system, omission of a required excipient, or a materially different pharmacokinetic profile.

FAQs About US Patent 10,583,121

Is US Patent 10,583,121 a composition-of-matter patent?

No. It is directed to a transdermal patch formulation and related treatment methods. It does not claim asenapine as a new chemical entity.

Does the patent cover any patch containing asenapine maleate?

No. The patch must satisfy the independent structural and pharmacokinetic limitations. Asenapine maleate is expressly recited in dependent claims, but the salt alone does not establish infringement.

Can a generic company launch an oral asenapine product before 2036?

Potentially, subject to separate patents, FDA requirements, and any Orange Book-listed patents covering the oral product. US Patent 10,583,121 principally concerns transdermal delivery.

What test would be needed to evaluate infringement?

The product would require formulation analysis, polymer identification, excipient quantification, drug-loading calculations, and pharmacokinetic testing using the claim's AUC2-120 and metabolite methodology.

Is Secuado protected by biosimilar exclusivity?

No. Secuado contains a small-molecule drug. Any competing product would use an ANDA or NDA pathway rather than the biosimilar pathway.

References

  1. U.S. Food and Drug Administration. (2009). FDA approves Saphris (asenapine) for schizophrenia and bipolar disorder. FDA.

  2. U.S. Food and Drug Administration. (2019). FDA approves new transdermal formulation of asenapine for schizophrenia. FDA.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

  4. U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,583,121: Patch for administering asenapine. U.S. Department of Commerce.

  5. Noven Pharmaceuticals, Inc. (2019). Secuado (asenapine) transdermal system prescribing information. U.S. Food and Drug Administration.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,583,121

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-001 Oct 11, 2019 RX Yes Yes 10,583,121 ⤷  Start Trial Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Start Trial
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-002 Oct 11, 2019 RX Yes No 10,583,121 ⤷  Start Trial Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Start Trial
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-003 Oct 11, 2019 RX Yes No 10,583,121 ⤷  Start Trial Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,583,121

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2012-165793Jul 26, 2012
Japan2013-078583Apr 4, 2013

International Family Members for US Patent 10,583,121

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 104487071 ⤷  Start Trial
China 104487072 ⤷  Start Trial
China 104507472 ⤷  Start Trial
European Patent Office 2878298 ⤷  Start Trial
European Patent Office 2878299 ⤷  Start Trial
European Patent Office 2878300 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.